Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavaleukin Alfa in Steroid-Refractory cGVHD
NCT03422627Phase 2Terminated
- Sponsor
- Amgen
- Start
- Apr 2018
- Primary completion
- Oct 2022
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 4
01
Overview
A Phase 2 trial of efavaleukin alfa in chronic graft-versus-host disease (cGVHD), sponsored by Amgen. Started Apr 2018; status: terminated.
02
Drugs
efavaleukin alfa
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT03422627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03422627.